Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results